-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Benzinga·10/21/2026 12:58:31
Listen to the news
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.